Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?

Clinics (Sao Paulo). 2019 Sep 26;74:e1424. doi: 10.6061/clinics/2019/e1424. eCollection 2019.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Brazil
  • Crohn Disease*
  • Gastrointestinal Agents
  • Humans
  • Infliximab

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Infliximab